SAN DIEGO, CA, USA I June 24, 2013 I Sorrento Therapeutics, Inc. (OTCQB: SRNE; Sorrento) announced today that preclinical data of its therapeutic fully human anti-PD-L1 and anti-PD-1 monoclonal antibodies (mAbs) will be presented at the IBC 8th Annual Next Generation Protein Therapeutics Summit, June 26 – 28 in San Diego.
In recent clinical studies,[1] immunomodulatory anti-PD-1 and anti-PD-L1 antibodies have shown great promise for the treatment of solid tumors. By blocking immunosuppressive signals on cancer cells directed against infiltrating T cells, the patients’ anti-tumor immune response might be rejuvenated.
“We believe these preclinical data are the first demonstration of potent immunomodulatory anti-PD-L1 and anti-PD-1 antibodies obtained from a fully human antibody library rather than mouse-based technologies,” said Henry Ji, Ph.D., Sorrento’s President and CEO. “Overall, these data illustrate the potential of Sorrento’s G-MAB® library technology for discovery and development of fully human therapeutic antibodies against clinically valuable drug targets,”
The poster presentation titled “Human anti-PD-L1 and anti-PD-1 mAbs Identified from an Antibody Library Exhibit Potent Immune Cell Activation” is authored by J. Dixon Gray, Heyue Zhou, Edwige Gros, Kimberly Johnson, Gunnar F. Kaufmann, and Randy Gastwirt.
About Sorrento Therapeutics, Inc.
Sorrento Therapeutics, Inc. is a publicly-traded, development-stage biopharmaceutical company engaged in the discovery, acquisition, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs in the Unites States, Europe and additional international markets. Sorrento Therapeutics‘ primary therapeutic focus is oncology but it is also developing therapeutics products for other indications, including inflammation, metabolic, and infectious diseases. Sorrento Therapeutics’ proprietary G-MAB® fully-human antibody library platform was designed to facilitate the rapid identification and isolation of highly specific antibody therapeutic product candidates that bind to disease targets appropriate for antibody therapy.
More information is available at www.sorrentotherapeutics.com
SOURCE: Sorrento Therapeutics
Post Views: 116
SAN DIEGO, CA, USA I June 24, 2013 I Sorrento Therapeutics, Inc. (OTCQB: SRNE; Sorrento) announced today that preclinical data of its therapeutic fully human anti-PD-L1 and anti-PD-1 monoclonal antibodies (mAbs) will be presented at the IBC 8th Annual Next Generation Protein Therapeutics Summit, June 26 – 28 in San Diego.
In recent clinical studies,[1] immunomodulatory anti-PD-1 and anti-PD-L1 antibodies have shown great promise for the treatment of solid tumors. By blocking immunosuppressive signals on cancer cells directed against infiltrating T cells, the patients’ anti-tumor immune response might be rejuvenated.
“We believe these preclinical data are the first demonstration of potent immunomodulatory anti-PD-L1 and anti-PD-1 antibodies obtained from a fully human antibody library rather than mouse-based technologies,” said Henry Ji, Ph.D., Sorrento’s President and CEO. “Overall, these data illustrate the potential of Sorrento’s G-MAB® library technology for discovery and development of fully human therapeutic antibodies against clinically valuable drug targets,”
The poster presentation titled “Human anti-PD-L1 and anti-PD-1 mAbs Identified from an Antibody Library Exhibit Potent Immune Cell Activation” is authored by J. Dixon Gray, Heyue Zhou, Edwige Gros, Kimberly Johnson, Gunnar F. Kaufmann, and Randy Gastwirt.
About Sorrento Therapeutics, Inc.
Sorrento Therapeutics, Inc. is a publicly-traded, development-stage biopharmaceutical company engaged in the discovery, acquisition, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs in the Unites States, Europe and additional international markets. Sorrento Therapeutics‘ primary therapeutic focus is oncology but it is also developing therapeutics products for other indications, including inflammation, metabolic, and infectious diseases. Sorrento Therapeutics’ proprietary G-MAB® fully-human antibody library platform was designed to facilitate the rapid identification and isolation of highly specific antibody therapeutic product candidates that bind to disease targets appropriate for antibody therapy.
More information is available at www.sorrentotherapeutics.com
SOURCE: Sorrento Therapeutics
Post Views: 116
